Medium February 7, 2024
The Daily Edition

We all want to know where we come from. If you’ve ever told someone you want to learn more about your ancestry (as I have) they’ll probably point you toward 23andMe, the genetic testing company that went public in 2021 and was briefly valued at $6 billion (or about $1 billion more than what Reddit is eyeing as a valuation for its expected IPO later this year).

It turns out 23andMe is now worth almost $0. I’ve never spit into one of their tubes, but I can see why. Because DNA tests only need to be done once, 23andMe has a business model that doesn’t attract repeat customers. Also, the data isn’t placed in context or paired with genealogical records,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Insurance, Pharma / Biotech, Precision Medicine
Phenomix Sciences Raises $7.8M to Acclerate Obesity Precision Medicine Adoption
Sylvester Cancer Center Launches Precision-Medicine Focused Brain Tumor Institute
Largest GWAS for Breast Cancer in Women of African Ancestry Reveals Key Variants
New Study Links Ribosomal DNA Copy Number with Disease Risk
Navigating the Complexities of Payment for Genetic Testing

Share This Article